Market Access Obstructs Newer Biologic and JAK Adoption in Rheumatoid Arthritis
Download Report Overview Despite frequent involvement with payers for the approval of biologics/JAKs in RA, rheumatologists report that their use is heavily impacted by the negative reimbursement and access environment, according to a recent report from Spherix Global Insights. August 19, 2016 – Cambridge, Massachusetts. While the majority of surveyed rheumatologists (n=100) report that access […]
Rheumatologists Report Widespread Adoption and Anticipated Gains for Celgene’s Otezla in Psoriatic Arthritis
TNF share expected to erode as Otezla sees greater adoption, according to Spherix Global Insights, GmbH September 8, 2015 – Zug, Switzerland – Feedback gathered from 101 US rheumatologists during late July and early August reveals a major shift in PsA treatment focused on the uptake and expanded use of Otezla. According to the latest […]
Rheumatologists Plan to Increase their Use of Pfizer’s Xeljanz, Janssen’s Simponi and Roche’s Actemra in the Next Month
Over 40% of current Xeljanz users expect to increase use, with many rheumatologists initiating the agent prior to biologics, according to Spherix Global Insights, GmbH September 1, 2015 – Zug, Switzerland – Feedback gathered from 101 rheumatologists in August reveals that while anti-TNF inhibitors remain entrenched in most practices, use of Xeljanz, Actemra and Simponi […]
